Eton Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
of $15.5M (73% margin), GAAP net income of $1.5M and adjusted EBITDA of $6.2M (29%), though operating cash flow swung to an $11.6M outflow and cash totaled $25.9M at quarter end. DESMODA launch: The FDA-approved oral liquid desmopressin was launched in late February with “incredibly encouraging” early demand, a 90-day adult pilot underway, an estimated U.S. addressable market of ~3–4k children and ~9–10k adults, and patents through 2044; Eton reaffirmed pediatric peak sales guidance of $30–50M while viewing adults as incremental. Outlook and portfolio moves: Eton expects 2026 revenue $110M and adjusted EBITDA margin =30%, completed a $14M cash acquisition of HEMANGEOL with a May relaunch, and set longer-term goals including a $200M run-rate by end-2027, 50% adjusted EBITDA margin in 2028, and $500M revenue by 2030. Interested in Eton Pharmaceuticals, Inc.? Here are five stocks we like better. Eton Pharmaceuticals (NASDAQ:ETON) reported fourth quarter 2025 product revenue of $2
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $37.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by B. Riley Financial, Inc. from $26.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $30.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ETON
Earnings
- 3/19/26 - Beat
ETON
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/6/26 - Form S-8
- ETON's page on the SEC website